(3,4-Dihydro-2h-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl)-methanone | 409345-29-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (3,4-Dihydro-2h-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl)-methanone
• 英文别名: 3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl-(4-methoxycyclohexyl)methanone
• CAS: 409345-29-5；409345-31-9
• 化学式: C₂₀H₂₃NO₃
• 分子量: 325.4
• InChiKey: QOTAQTRFJWLFCR-UHFFFAOYSA-N

物化性质

• 熔点：
  102-104°C
• 沸点：
  502.5±50.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION
  申请人：Jensen Ralph J.

  公开号：US20150038464A1

  公开（公告）日：2015-02-05

  Disclosed herein are methods of increasing retinal responsiveness to light in a subject, such as a subject with retinal degeneration. The disclosed methods include administering one or more compounds that decrease or inhibit γ-aminobutyric acid (GABA) signaling to a subject with retinal degeneration. In some embodiments, the methods include selecting a subject with retinal degeneration and administering a γ-aminobutyric acid C (GABA C ) receptor antagonist to the subject. In one example, the GABA C receptor antagonist is (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA). In other embodiments, the methods include selecting a subject with retinal degeneration and administering a metabotropic glutamate receptor (mGluR) antagonist to the subject. In one example, the mGluR antagonist is a mGlu1 receptor antagonist (for example, JNJ16259685).
• US7517517B2
  申请人：——

  公开号：US7517517B2

  公开（公告）日：2009-04-14
• US7629468B2
  申请人：——

  公开号：US7629468B2

  公开（公告）日：2009-12-08
• [EN] METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION<br/>[FR] PROCÉDÉS D'AUGMENTATION DE LA RÉACTIVITÉ À LA LUMIÈRE CHEZ UN SUJET AVEC DÉGÉNÉRESCENCE DE LA RÉTINE
  申请人：US DEPT VETERANS AFFAIRS

  公开号：WO2013126088A1

  公开（公告）日：2013-08-29

  Disclosed herein are methods of increasing retinal responsiveness to light in a subject, such as a subject with retinal degeneration. The disclosed methods include administering one or more compounds that decrease or inhibit γ-aminobutyric acid (GABA) signaling to a subject with retinal degeneration. In some embodiments, the methods include selecting a subject with retinal degeneration and administering a γ-aminobutyric acid C (GABAC) receptor antagonist to the subject. In one example, the GABAC receptor antagonist is (1,2,5,6-tetrahydropyridin-4yl)methylphosphinic acid (TPMPA). In other embodiments, the methods include selecting a subject with retinal degeneration and administering a metabotropic glutamate receptor (mGluR) antagonist to the subject. In one example, the mGluR antagonist is a mGlu1 receptor antagonist (for example, JNJ16259685).